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Forty-two participants with cerebral palsy were recruited for a
study examining traditional and novel indicators of cardiovascular
risk (McPhee et al., 2015 [1]). Data pertaining to the prevalence of
obesity, smoking, hypertension, and metabolic risk are provided.
These data are presented along with the scoring methods used in
evaluation of the study participants. Percentages are included for
comparative purposes with the existing literature.
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
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Value of the data
 There is a paucity of literature reporting the prevalence of cardiovascular disease risk in adults with
cerebral palsy; a population believed to be at elevated risk due to their mobility impairments.
 These data are included for comparative purposes of the existing literature, and may inform sys-
tematic and/or meta-analytic reviews.
 These data may inform future studies in non-ambulatory adults with cerebral palsy as they
presented greater absolute risk for cardiovascular disease.1. Data, experimental design, materials and methods
1.1 Data
In the present data, we highlight the prevalence of cardiovascular and metabolic risk in adults with
cerebral palsy (CP) who are either ambulatory or non-ambulatory. We provide cardiovascular disease
(CVD) risk factor information that is consistent with predictors from the Framingham Heart Study [2].
We also present individuals who are at elevated risk for CVD based on obesity, and lipid and glucose
levels.
1.2 Subjects
Study participants’ characteristics are described elsewhere [1].
1.3 Methods
Measurements of supine brachial artery systolic blood pressure, diastolic blood pressure, and
mean arterial pressure were obtained using an automated sphygmomanometer (Dinamap Pro 100,
Critikon LCC, Tampa, Fla, USA) in all 42 participants. Hypertension was deﬁned as per the Eighth Joint
National Committee [3].
Supine height without shoes was measured to the nearest 0.5 cm using an anthropometric tape
measure. Body mass was measured to the nearest 0.1 kg using a digital wheelchair scale (Detecto
Scales, FHD Series, Webb City, Missouri, USA). Body mass index (BMI) was determined by dividing the
participant's weight (kg) by their height squared (m2). Waist circumference was measured while in a
supine position using an adapted technique as per the National Institutes of Health (NIH) [4]. All
anthropometric measures were collected in all 42 participants.
Participants provided a 12 h fasting venous blood sample for serum analysis. Thirty-three of the 42
participants provided a venous blood sample. Blood draws were not acquired on one ambulatory and
Table 1
Prevalence of obesity and cardiovascular and metabolic risk factors among participants.




BMIZ30 kg/m2 9 (21.4) 3 (21.4) 6 (21.4)
Central obesity 12 (28.6) 4 (28.6) 8 (28.6)
Hypertensive BP 6 (14.3) 0 6 (21.4)
Hypercholesterolemia 13 (39.4) 5 (38.5) 8 (40.0)
Smoker 3 (7.14) 2 (14.3) 1 (3.57)
Low HDL-C 8 (24.2) 2 (15.4) 6 (30.0)
High LDL-C 13 (39.4) 6 (46.2) 7 (35.0)
TC/HDL-C 4 (12.1) 1 (7.7) 3 (15.0)
Hypertriglyceridemia 8 (24.2) 2 (15.4) 6 (30.0)
Hyperglycemia 17 (51.5) 6 (46.1) 11 (55.0)
Values are n (%).
All metabolic markers (ambulatory n¼13; non-ambulatory n¼20).
P.G. McPhee et al. / Data in Brief 5 (2015) 967–970 969eight non-ambulatory participants due to contractures, spasticity, or insufﬁcient vein size. The
samples were analyzed for lipids; total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), TC/HDL-C, and triglycerides. Participant labeled Eppen-
dorf tubes were sent to Hamilton Regional Laboratory Medicine Program – McMaster Medical Centre
Campus for analysis of the previously identiﬁed lipid markers. Glucose was examined using the
Glucose Hexokinase Reagent Set (Pointe Scientiﬁc, Inc. Canton, MI, USA). All coefﬁcients of variation
between duplicates were o10% for each metabolic marker.
Descriptive results of lifestyle-related and metabolic risk factors are shown in Table 1. Clinical
cholesterol levels for CVD risk were 45.20 mmol/L for TC; o1.04 mmol/L for HDL-C; 43.40 mmol/L
for LDL-C; 46.0 for TC/HDL-C as per Canadian Cardiovascular Society guidelines [5]. Central obesity
was deﬁned as having a waist circumference Z102 cm for men or Z88 cm for women as per the NIH
[4]. A BMI Z30 kg/m2 was deﬁned as being obese as per the NIH [4]. Hyperglycemia was deﬁned as
Z100 mg/dL as per American Diabetes Association [6].Acknowledgments
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